REG - Nuformix PLC - Second tranche of Lanstead subscription shares

NuformixAnnouncement

12/04/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220412:nRSL0005Ia&default-theme=true

RNS Number : 0005I  Nuformix PLC  12 April 2022

12 April 2022

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Second tranche of Lanstead subscription shares

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that further to the notifications of 14 December 2021 and 17 January
2022 relating to its subscription and associated sharing arrangements with
Lanstead Capital Investors L.P. ("Lanstead"), application has now been made
for trading on the Standard Segment of the Official List and the Main Market
of the London Stock Exchange ("Admission") for the second tranche of the
subscription, comprising 88,000,000 Ordinary Shares (the "Second Subscription
Shares") for gross proceeds of £1,320,000 and the associated 5,700,000 Second
Value Payment Shares.

 

Full details of the subscription and associated sharing agreements and the
Second Value Payment Shares are set out in the earlier announcements
referenced above.

 

Admission and dealings in the Second Subscription Shares and the Second Value
Payment Shares, all of which will rank pari passu with the existing Ordinary
Shares, are expected to commence at 8.00 am on 14 April 2022.

 

Total Voting Rights

 

Following Admission of the Second Subscription Shares and the Second Value
Payment Shares the Company's enlarged issued share capital will comprise
709,309,368 Ordinary Shares with voting rights.  The figure of 709,309,368
Ordinary Shares may therefore be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.

 

 

Enquiries:

 

 Nuformix plc
 Dr Alastair Riddell, Executive Chairman           Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGPUCPCUPPGWG